Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

Last updated: April 8, 2025
Sponsor: The Archer-Daniels-Midland Company
Overall Status: Active - Recruiting

Phase

N/A

Condition

Colic

Treatment

Placebo

Probiotic

Clinical Study ID

NCT05432479
PCTB202010
  • Ages 3-12
  • All Genders

Study Summary

This study evaluates the efficacy of single strain probiotic administered in a form of a sachet in the treatment of infant colic in infants 3-12 weeks old.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Gestational age of minimum 37 weeks.

  • Birthweight of minimum 2500 g (5.5 lb.).

  • Age of greater than 3 weeks and less than 12 weeks at enrolment.

  • Confirmed Infantile colic defined as: parental report of crying and/or fussing ≥3hours/day for ≥3 days/week, confirmed prior to enrolment with an infant behaviourdiary recording >3 hours of crying in a 24-hour period (eDiary App completed dailyduring run-in period & for duration of study).

  • Participant Informed Consent form signed by parent or legal guardian.

  • Infant is considered healthy following physical exam.

  • Parents/Caregivers are willing to comply with the trial procedures, and the motherof the infant can attend all three trial visits

Exclusion

Exclusion Criteria:

  • Use of antibiotics by the infant within 2-weeks prior to the screening visit orduring the run-in period of the trial.

  • Use of probiotic supplements from child's birth to enrolment (this includes infantformulas containing probiotics).

  • Need for hospitalization (defined as readmission to a hospital ward after initialdischarge following delivery).

  • Congenital disorders that, in the opinion of the investigator, would impact thegastrointestinal tract.

  • Failure to thrive.

  • Known lactose or gluten intolerance.

  • Known allergy to cow's milk proteins, fish, or any of the substances of the trialproduct or placebo.

  • Known other causes for abdominal pain (e.g., pyloric stenosis).

  • Participation in any other interventional clinical study.

  • Immuno-compromised participant or participant with other severe chronic disorder.

  • Use of probiotic supplements by breastfeeding mother from child's birth toenrolment.

  • Use of antibiotics by breastfeeding mother within 2-weeks prior to the screeningvisit or during the run-in period of the trial.

  • Any Participant/Parent/Caregiver who is an employee of the investigational site oran Atlantia Clinical Trials employee or their close family member or a member oftheir household.

Study Design

Total Participants: 80
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
September 30, 2022
Estimated Completion Date:
May 31, 2026

Connect with a study center

  • Pulse Multispeciality Hospital,

    Pune, Maharashtra Pune 411 041
    India

    Active - Recruiting

  • Atlantia Food Clinical Trials

    Chicago, Illinois 60611
    United States

    Completed

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.